Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis
Open Access
- 1 December 2021
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 6 (12), 1451-1460
- https://doi.org/10.1001/jamacardio.2021.3444
Abstract
The COVID-19 pandemic is challenging the global public health and health care sectors in many ways. The public health, health care, and related supply chain infrastructures were unprepared and underfunded for this crisis. Perhaps the most impressive and timely response to COVID-19 has been the unprecedentedly rapid production of effective vaccines against this infectious disease, while effective therapeutics and cost-effective diagnostics have lagged.1Keywords
This publication has 71 references indexed in Scilit:
- Cerebral Venous ThrombosisCirculation, 2012
- Diagnosis and Management of Cerebral Venous ThrombosisStroke, 2011
- Venous Thromboembolic Events After Cerebral Vein ThrombosisStroke, 2010
- Safety of thrombolysis in cerebral venous thrombosisThrombosis and Haemostasis, 2010
- Cerebral Venous and Sinus Thrombosis in WomenStroke, 2009
- Epidemiology and Risk Factors for Venous ThrombosisSeminars in Hematology, 2007
- Delay in Hospital Admission of Patients with Cerebral Vein and Dural Sinus ThrombosisCerebrovascular Diseases, 2005
- Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritisArthritis & Rheumatism, 2003
- Heparin-induced thrombocytopeniaJournal of Thrombosis and Haemostasis, 2003
- Thrombolytics for Cerebral Sinus ThrombosisCerebrovascular Diseases, 2003